Grifols, S.A.
General ticker "GIFOF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $6.0B (TTM average)
Grifols, S.A. follows the US Stock Market performance with the rate: 5.9%.
Estimated limits based on current volatility of 0.0%: low 8.85$, high 8.85$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2026-07-01, amount 0.11$ (Y2.49%)
- Total employees count: 25247 as of 2025
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.80$, 12.11$]
- 2026-12-31 to 2027-12-31 estimated range: [9.46$, 14.23$]
Financial Metrics affecting the GIFOF estimates:
- Positive: with PPE of 10.2 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 16.43
- Positive: 15.29 < Operating cash flow per share per price, % of 20.31
- Positive: 25.20 < Shareholder equity ratio, % of 26.74 <= 34.41
- Positive: Inventory ratio change, % of -2.14 <= -1.30
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.00
- Positive: Industry earnings per price (median), % of 6.62 > 6.58
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
Short-term GIFOF quotes
Long-term GIFOF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €6,591.98MM | €7,212.38MM | €7,521.39MM |
| Operating Expenses | €5,792.58MM | €6,020.37MM | €6,285.85MM |
| Operating Income | €799.40MM | €1,192.02MM | €1,235.54MM |
| Non-Operating Income | €-575.38MM | €-748.02MM | €-620.69MM |
| Interest Expense | €516.06MM | €739.94MM | €576.00MM |
| R&D Expense | €395.28MM | €384.04MM | €425.86MM |
| Income(Loss) | €224.02MM | €444.00MM | €614.85MM |
| Taxes | €43.35MM | €231.19MM | €114.57MM |
| Net Income(Loss)* | €59.31MM | €156.92MM | €401.74MM |
| Stockholders Equity | €5,827.17MM | €5,883.73MM | €5,269.79MM |
| Inventory | €3,459.28MM | €3,560.10MM | €3,294.62MM |
| Assets | €21,441.05MM | €21,405.24MM | €19,703.98MM |
| Operating Cash Flow | €208.28MM | €902.17MM | €1,046.61MM |
| Capital expenditure | €295.42MM | €371.37MM | €264.90MM |
| Investing Cash Flow | €-397.64MM | €886.67MM | €-578.78MM |
| Financing Cash Flow | €186.04MM | €-1,358.71MM | €-528.80MM |
| Earnings Per Share** | €0.09 | €0.22 | €0.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.